Last reviewed · How we verify
Low-dose lipopolysaccharide
At a glance
| Generic name | Low-dose lipopolysaccharide |
|---|---|
| Also known as | LPS |
| Sponsor | Yale University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CBD-Microglia PET Study (EARLY_PHASE1)
- Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen (NA)
- Genetic Predictors of Analgesic Efficacy of Propranolol for Treating Postoperative Pain (PHASE2)
- Validation of the Analysis Methodology Behind the Use of Quantitative 18F-FDG PET/CT to Assess Lung Inflammation
- Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans (PHASE1)
- Inflammation and the Metabolic Syndrome in Humans (NA)
- Effects of Vasopressors on Immune Response (PHASE4)
- Study of Biomarkers of Airway Inflammation (0000-128) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |